Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Traws Pharma reports Phase 2a ratutrelvir data and plans Q4 resubmission for flu drug

The US biotech says its oral COVID-19 antiviral matched PAXLOVID on symptom resolution in a 92-subject study, while tivoxavir marboxil remains under an FDA clinical hold.

16 Nov 2026 · Traws Pharma, Inc. TRAW · Company news

Traws Pharma released its third-quarter results on 16 November 2026, alongside updates on its two lead antiviral programmes. The company reported final data from a Phase 2a study of ratutrelvir, its oral COVID-19 antiviral, and set out its plans for tivoxavir marboxil, a candidate for influenza prevention.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Traws Pharma, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →